Skip to content
Search

Latest Stories

£20 and £50 paper notes to expire by end of September

Businesses, including community pharmacies, that handle cash have been urged to prepare for the removal of £20 and £50 paper banknotes from circulation. The paper notes of both denominations will no longer be legal tender from Friday 30 September.

Cash handling experts Volumatic reminded businesses to make sure that they deposit any paper notes at banks by this date, and ensure they would not be accepting any further paper notes from customers from 1 October onwards.


“While businesses continue to face extra demands during the current cost-of living crisis, we’ve already seen evidence of an uplift in cash usage by consumers, who are now using cash more to help them budget more effectively,” Mike Severs, Sales and Marketing Director at Volumatic, said.

“With more consumers looking to spend their old paper notes before the end-of-September deadline, it’s really important to remember to deposit any paper notes you either already have within your business or receive throughout this month to your bank before the end of September.”

If retailers are unable to deposit paper notes at the bank, there is also the option of a postal exchange with the Bank of England or notes can be exchanged at selected Post Office branches.

Like the £5 and £10 notes before them, the paper £20 and £50 notes are being replaced by the new polymer banknotes, which were first issued in February 2020 and June 2021, respectively. And while these £20 and £50 polymer notes have replaced the majority of paper banknotes over the past couple of years, the Bank of England has estimated that there are still more than 14 billion paper £20 and £50 notes still in circulation.

The new notes are more durable, as they are made of plastic rather than paper, meaning fewer new notes will need to be issued over time. The notes are more state-of-the-art and therefore more secure, meaning they are far more difficult to forge.

Forged banknotes have caused headaches for retailers for many years, but since the £5 and £10 polymer notes were introduced in 2016-17, followed by the £20 and £50 notes more recently, completing the set, the UK has already seen a sharp decline in the number of counterfeit notes in circulation, Volumatic noted.

The Bank of England’s Banknote Statistics Data said that in 2021, typically less than 1 in every 40,000 banknotes were counterfeit in the UK, but that still equates to a face value of £2.7 million.

Volumatic said businesses can invest in its CounterCache intelligent (CCi) solution to help eliminate forgeries.

Currently used by businesses including Tesco, Morrisons, Wilko and the Co-op Food Group, CCi is an all-in-one unit that counts, detects 100% of forgeries and securely stores your cash, all at POS.

Notes cannot be touched or mislaid again until they reach the bank and the CCi also offers in-depth reporting for full visibility, and it can be integrated with any EPOS system or cash reconciliation software platform.

If a business has the need to count much larger volumes of cash, Volumatic’s Friction Note Counters can count banknotes quickly and accurately whilst at the same time detect all known forgeries.

The company added that both the CCi and its various friction note counter devices have passed the Bank of England’s framework test for banknote machines and forgery detectors, which means they will reject all known forgeries in circulation.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less